BioCentury
ARTICLE | Company News

AZN rejects TAPET option

March 19, 2001 8:00 AM UTC

AZN will not exercise its option to finance development of TAPET-CPG2, a Vion Pharmaceuticals (VION) bacterial vector combined with the CPG2 prodrug converting enzyme from Epttco (Abingdon, U.K.). VIO...